Actinomycosis is a rare kind of bacterial infection which is caused by a group of bacteria named actinomyces. This bacteria attacks various regions such as mouth, colon and vagina. Their most common location is around the jaw and lungs.
They slowly disrupt mucosa linings which can lead to infection. There can be many types of actinomycosis, cervicofacial actinomycosis, abdominal actinomycosis, pulmonary actinomycosis, pelvic actinomycosis and primary cutaneous actinomycosis.
Treatment of actinomycosis is performed by antimicrobial drugs, surgical management and also the combination of antibiotics and surgery. Treatment duration can vary from several months to a year depending on the severity of the disease.
These bacteria are sensitive to penicillin, therefore a drug Penicillin G is usually preferred for treating actinomycosis. Parental penicillin is administered initially through peripherally inserted central catheter line, with the transition to oral agents followed by amoxicillin.
There are many alternative in the actinomycosis market for allergic patients which include erythromycin, tetracycline and clindamycin. There is some evidence for some agents that shows good in-vitro activity might also be used as an alternative. This includes linezolid, azithromycin, vancomycin and fluoroquinolones.
Increasing prevalence of infectious diseases is expected to drive the growth of the actinomycosis market. Affordable treatment cost is also expected to drive the growth of the actinomycosis market. Increasing use of intrauterine devices is expected to drive the growth of actinomycosis market as women using it are at higher risk of getting infected.
Modern lifestyle has resulted in the weakening of the immune system, and people with the weak immune system are more vulnerable to get actinomycosis disease which in turn is expected to drive the growth of actinomycosis market.
Increasing dental problem is expected to drive the growth of the actinomycosis market, people who had oral abscess are more likely to get affected by actinomycosis. Prolonged and the high dose of antimicrobials drug is expected to become restraint for actinomycosis market.
Also, very few pieces of research and development because of the tedious and expensive process of antibiotic development in this area restrict the growth of the actinomycosis market.Based on drug class, benzylpenicillin is expected to be the most preferred drug in the global actinomycosis market, high dose of penicillin g is usually recommended followed by amoxicillin.
Based on the route of administration, the oral route is the most frequently used route of drug administration in the actinomycosis market. Based on the distribution channel, retail pharmacies are expected to be the most profitable segment in the global actinomycosis market.
Actinomycosis is a rare disorder, however, the rising population of the world and also the increasing numbers of infectious disease are responsible for driving the growth of the actinomycosis market.
North America is expected to have the highest market share of actinomycosis market due to the higher prevalence of the bacterial infection and easy availability of drugs in the region.
North America to be followed by Europe due to the higher adoption of antimicrobial drugs. Asia-Pacific is expected to be the fastest-growing actinomycosis market due to the rising population in countries like India and China.
Latin America market is expected to experience the constant growth rate in the actinomycosis market whereas the Middle East & Africa expected to be the least profitable market due to lower adoption of drugs.
The key participants operating in the global actinomycosis market are:
- Pfizer Inc,
- Johnson and Johnson Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Aurobindo Pharma Limited
- GlaxoSmithKline plc
- Fermenta Biotech Limited
- Abbott Laboratories
The report covers exhaustive analysis on:
- Actinomycosis market Segments
- Actinomycosis Market Dynamics
- Historical Actual Market Size, 2015 - 2019
- Actinomycosis market Size & Forecast 2020 to 2030
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
Impact of COVID19 on Actinomycosis Market
The outbreak of coronavirus is an unprecedented shock to the world’s economy. It is causing the disturbance in almost all industries. It has caused a huge impact on antibacterial drug development industries which in turn is affecting the actinomycosis market.
As coronavirus has become the main focus, all research institutes, biotech and pharmaceutical companies are appointed in collaboration work to deal with Covid-19. This led to the shifting of their focus and also all the resources from making antibiotics to coronavirus vaccines. This is hampering the productivity of actinomycosis drug development.
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
Actinomycosis market Segment
Actinomycosis market has been segmented on the basis of drug type, route of administration and distribution channel.
By drug class:
By distribution channel:
- Retail Pharmacies
- Hospital Pharmacies
- Drug store
- Online sales
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.